News 2016

Thuja Capital leads series A investment round in Indigo Diabetes

Date: 20/12/2016

20 December 2016, Utrecht (NL) and Ghent (B) — Indigo Diabetes nv (Indigo), a spin-off from Ghent University (UGent) and imec, today announces the successful closure of a 7 million Euros series-A financing round. The funding is provided by an international investment syndicate led by Thuja Capital Healthcare Fund II (The Netherlands) (more…)

argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients

Date: 15/12/2016

15 December 2016, Breda, the Netherlands / Ghent, Belgium – argenx today announced the initiation of a Phase I/II clinical trial of ARGX-110 in combination with azacitidine in newly diagnosed, elderly acute myeloid leukemia (AML) patients. (more…)

Cristal Therapeutics and iTeos Therapeutics announce strategic partnership

Date: 07/12/2016

7 December 2016, Maastricht, The Netherlands and Gosselies, Belgium –  Cristal Therapeutics and iTeos Therapeutics today announced a strategic partnership for the discovery, development and commercialization of optimized immuno anti-cancer drug candidates, (more…)

NutriLeads announces positive outcome of proof-of-concept study in humans

Date: 24/11/2016

24 November 2016, Wageningen, The Netherlands. NutriLeads B.V. today announces the positive outcome of a proof of concept study in humans demonstrating that its lead ingredient IMPP-1 is safe, well tolerated and supports immune function in humans. (more…)

Nutrileads wins prestigious Eurostars grant

Date: 21/11/2016

21 November 2016, Wageningen, The Netherlands. NutriLeads B.V., a Dutch Nutrition & Health startup has won a prestigious Eurostars grant to support the development of its lead ingredient IMPP-1 for application in medical foods. Nutrileads (as consortium leader) and 4 partners from the Netherlands, Germany and Finland have been awarded a € 2 million (more…)

Thuja Capital Healthcare Fund II invests in Molecular Imaging Laboratories (MILabs)

Date: 11/10/2016

11 October 2016, Utrecht – Today Utrecht-based MILabs announced that it successfully closed an investment round with Thuja Capital Healthcare Fund II and Value Creation Capital/TechNano Fund. (more…)

NightBalance closes EUR 12.5 million Series B financing to support commercial rollout in Europe and enter the U.S. market with its innovative sleep apnea device

Date: 05/07/2016

5 July 2016, Delft, the Netherlands – NightBalance BV, a leading innovator of obstructive sleep apnea (OSA) technology, today announced the completion of a EUR 12.5 million Series B financing round led by INKEF Capital and Gilde Healthcare Partners. Existing investors Thuja Capital, Health Innovation Fund, and Van Herk Ventures also participated. (more…)

argenx announces initial results from Phase 1 multiple ascending dose study of ARGX-113 in healthy volunteers

Date: 30/06/2016

30 June 2016 – Breda, the Netherlands / Ghent, Belgium – argenx, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced initial results from its Phase 1 multiple ascending dose (MAD) study of ARGX-113 (more…)

Investeringsmaatschappijen zien run op medische startups

Date: 14/06/2016

14 June 2014 – The Dutch financial newspaper Financieele Dagblad published an article (in Dutch language) about several funds that closed successfully in recent days, among which Thuja Capital Healthcare Fund II. See the original article here:
FD artikel

New capital for medical innovations: Thuja Capital successfully closes new fund

Date: 09/06/2016

9 June 2016, Utrecht – Thuja Capital Management (“Thuja”) has successfully closed a new venture capital fund, Thuja Capital Healthcare Fund II, with a fund size of EUR 34M. The fund will be used for investing in young Dutch and Belgian companies that develop innovative products for medical applications. (more…)

argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111

Date: 03/06/2016

3 June 2016, Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced data published in conjunction with the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting (Chicago, USA) (more…)

NutriLeads announces collaboration with DSM Nutritional Products

Date: 26/05/2016

26 May 2016, Wageningen, The Netherlands – Dutch nutritional health ingredients startup NutriLeads B.V. announces the signing of a collaboration agreement with DSM Nutritional Products for the further development of its lead ingredient. (more…)

Cristal Therapeutics announces appointment of Edwin Klumper as Chief Medical Officer

Date: 28/04/2016

28 April 2016, Maastricht, The Netherlands – Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform, today announced the appointment of Edwin Klumper as Chief Medical Officer. (more…)

argenx and AbbVie to collaborate on ARGX-115 against novel immuno-oncology target

Date: 21/04/2016

21 April 2016 — AbbVie (NYSE:ABBV), a global biopharmaceutical company, and argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune (more…)

Argenx’s partner Bird Rock Bio demonstrates potential for gerilimzumab, a novel SIMPLE antibody™ against IL-6 to treat rheumatoid arthritis

Date: 16/03/2016

16 March 2016 – Breda, The Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX) today reported that its partner Bird Rock Bio (formerly RuiYi) has announced that gerilimzumab, a novel SIMPLE Antibody™ neutralizing the IL-6 cytokine, has demonstrated safety and pharmacokinetics that support low, infrequent dosing and the potential for favorable pricing. (more…)

argenx receives milestone payment in LEO Pharma collaboration

Date: 02/02/2016

2 February 2016, Breda, The Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced it has received a milestone payment in connection with its collaboration with LEO Pharma. The companies have selected a lead cell line for manufacture of the licensed SIMPLE AntibodyTM candidate, in development for the treatment of inflammatory skin conditions. (more…)

argenx announces initial results from a Phase 1 single ascending dose study of ARGX-113 in healthy volunteers

Date: 06/01/2016

6 January 2016, Breda, The Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced that it has completed the dose-escalation part of a Phase 1 study of ARGX-113. (more…)